MORRIS PLAINS, N.J., May 26 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
(Nasdaq: IMMU), announced today that it will host a conference call and
webcast at 9:00 am for the purposes of discussing the matters reported in a
Current Report on Form 8-K filed yesterday, May 25, 2005.
Conference Call Details
A conference call and webcast is scheduled for today, Thursday, May 26,
2005, at 9 a.m. Eastern time. The call will be broadcast live on the Internet
and can be accessed by visiting the Investor Relations section of the
Company's Web site at http://www.immunomedics.com . The conference call can
also be accessed by dialing (877) 960-9066 for domestic callers and
(517) 308-9043 for international callers. The passcode for both is IMMU.
Interested parties should call at least five minutes prior to the conference
call to register. A replay of the call will be available until June 9, 2005.
The replay dial-in numbers are (800) 685-1235 for domestic callers and (203)
369-3419 for international callers. After the live webcast, the call will
remain available on the Company's Web site, http://www.immunomedics.com, for a
month.
About Immunomedics
Immunomedics is a biopharmaceutical company focused on the development of
monoclonal, antibody-based products for the targeted treatment of cancer,
autoimmune and other serious diseases. We have developed a number of advanced
proprietary technologies that allow us to create humanized antibodies that can
be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics or toxins, in each case to create
highly targeted agents. Using these technologies, we have built a pipeline of
therapeutic product candidates that utilize several different mechanisms of
action. We are currently preparing to enter our lead product candidate,
epratuzumab, into two pivotal Phase III trials for the treatment of patients
with moderate and severe lupus. At present, there is no cure for lupus and no
new lupus treatment drug has been approved in the U.S. in the last 40 years.
We believe that our portfolio of intellectual property, which includes
approximately 90 patents issued in the United States, and more than 250 other
issued patents worldwide, protects our product candidates and technologies.
Visit our web site at http://www.immunomedics.com .
This release, in addition to historical information, may contain forward-
looking statements made pursuant to the Private Securities Litigation Reform
Act of 1995. Such statements, including statements regarding clinical trials,
out-licensing arrangements, and capital raising activities, involve
significant risks and uncertainties and actual results could differ materially
from those expressed or implied herein. Factors that could cause such
differences include, but are not limited to, risks associated with new product
development (including clinical trials outcome and regulatory
requirements/actions), competitive risks to marketed products and availability
of financing and other sources of capital, as well as the risks discussed in
the Company's Annual Report on Form 10-K for the fiscal year ended June 30,
2004. The Company is not under any obligation, and the Company expressly
disclaims any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise.
For More Information:
Dr. Chau Cheng
Associate Director, Investor Relations & Business Analysis
(973) 605-8200, extension 123
ccheng@immunomedics.com
SOURCE Immunomedics, Inc.
 back to top
Related links:
http://www.Immunomedics.com
Company News On-Call:
http://www.prnewswire.com/comp/113121.html
CONTACT:
Dr. Chau Cheng, Associate Director, Investor
Relations & Business Analysis, +1-973-605-8200, ext. 123,
ccheng@immunomedics.com
|
